心电图筛查心房颤动:美国预防服务工作组证据报告与系统综述
该系统综述评估了65岁以上无症状成人经心电图筛查非瓣膜性心房颤动的证据及卒中预防治疗。抗凝治疗降低卒中与死亡风险但增加出血,且筛查检出后治疗的健康获益尚未明确。
要点
- 心电图系统筛查较不筛查可增加心房颤动检出(12个月绝对增幅0.6%至2.8%),但未优于脉搏触诊筛查。
- 华法林降低缺血性卒中(RR 0.32)与全因死亡(RR 0.68)风险,但增加出血风险。
- 尚无研究评估筛查检出并治疗的无症状老年人与常规检出的健康结局差异。
核心结论
- 心电图筛查可检出既往未知的心房颤动,但未显示比脉搏触诊筛查检出更多病例。
- 抗凝治疗降低卒中与全因死亡风险但增加出血,筛查检出后治疗的健康获益未经试验证实。
研究设计与样本
- 纳入英文随机临床试验、评估心房颤动检出率或筛查危害的前瞻性队列研究及评估卒中预防治疗的系统综述。
主要发现
- 华法林(平均1.5年)与缺血性卒中风险降低相关(RR 0.32,95%CI 0.20-0.51),与全因死亡风险降低相关(RR 0.68,95%CI 0.50-0.93),与出血风险增加相关(5项试验,n=2415)。
- 网络荟萃分析报告NOACs与卒中及系统性栓塞复合结局风险显著降低相关(校正比值比0.32-0.44),出血风险增加(校正比值比1.4-2.2),但置信区间宽且组间差异无统计学意义。
关键数值与推荐
- 华法林治疗平均1.5年:缺血性卒中RR 0.32(95%CI 0.20-0.51),全因死亡RR 0.68(95%CI 0.50-0.93),出血风险增加(5项试验,n=2415)。
- NOACs对比安慰剂或对照:卒中及系统性栓塞复合结局校正比值比0.32-0.44,出血校正比值比1.4-2.2,差异无统计学意义。
临床怎么用
- 心电图筛查可发现无症状老年人心房颤动,但筛查策略选择时需考虑其未优于脉搏触诊筛查。
- 筛查检出心房颤动后的抗凝治疗决策应权衡卒中预防获益与出血风险,参照治疗试验证据。
局限性
- 无研究评估筛查对比不筛查的健康结局。
- 无研究比较筛查与不筛查的潜在危害。
- 治疗试验参与者非筛查检出,且多数为长期持续性心房颤动,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Atrial fibrillation is the most common arrhythmia and increases the risk of stroke. OBJECTIVE: To review the evidence on screening for nonvalvular atrial fibrillation with electrocardiography (ECG) and stroke prevention treatment in asymptomatic adults 65 years or older to inform the US Preventive Services Task Force. DATA SOURCES: MEDLINE, Cochrane Library, and trial registries through May 2017; references; experts; literature surveillance through June 6, 2018. STUDY SELECTION: English-language randomized clinical trials (RCTs), prospective cohort studies evaluating detection rates of atrial fibrillation or harms of screening, and systematic reviews evaluating stroke prevention treatment. Eligible treatment studies compared warfarin, aspirin, or novel oral anticoagulants (NOACs) with placebo or no treatment. Studies were excluded that focused on persons with a history of cardiovascular disease. DATA EXTRACTION AND SYNTHESIS: Dual review of abstracts, full-text articles, and study quality. When at least 3 similar studies were available, random-effects meta-analyses were conducted. MAIN OUTCOMES AND MEASURES: Detection of previously undiagnosed atrial fibrillation, mortality, stroke, stroke-related morbidity, and harms. RESULTS: Seventeen studies were included (n = 135 300). No studies evaluated screening compared with no screening and focused on health outcomes. Systematic screening with ECG identified more new cases of atrial fibrillation than no screening (absolute increase, from 0.6% [95% CI, 0.1%-0.9%] to 2.8% [95% CI, 0.9%-4.7%] over 12 months; 2 RCTs, n = 15 803), but a systematic approach using ECG did not detect more cases than an approach using pulse palpation (2 RCTs, n = 17 803). For potential harms, no eligible studies compared screening with no screening. Warfarin (mean, 1.5 years) was associated with a reduced risk of ischemic stroke (relative risk [RR], 0.32 [95% CI, 0.20-0.51]) and all-cause mortality (RR, 0.68 [95% CI, 0.50-0.93]) and with increased risk of bleeding (5 trials, n = 2415). Participants in treatment trials were not screen detected, and most had long-standing persistent atrial fibrillation. A network meta-analysis reported that NOACs were associated with a significantly lower risk of a composite outcome of stroke and systemic embolism (adjusted odds ratios compared with placebo or control ranged from 0.32-0.44); the risk of bleeding was increased (adjusted odds ratios, 1.4-2.2), but confidence intervals were wide and differences between groups were not statistically significant. CONCLUSIONS AND RELEVANCE: Although screening with ECG can detect previously unknown cases of atrial fibrillation, it has not been shown to detect more cases than screening focused on pulse palpation. Treatments for atrial fibrillation reduce the risk of stroke and all-cause mortality and increase the risk of bleeding, but trials have not assessed whether treatment of screen-detected asymptomatic older adults results in better health outcomes than treatment after detection by usual care or after symptoms develop.
引用
- Jonas DE, Kahwati LC, Yun JDY, et al. Screening for Atrial Fibrillation With Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018. PMID: 30088015. doi:10.1001/jama.2018.4190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。